Primary retroperitoneal mucinous cystadenocarinoma is extremely rare with only five case reported in the literature.Primary mucinous adenocarcinoma is apparent that a primary retroperitoneal process in development results in tissue susceptible to malignants degeneration. It is impossible to clarify the precise defect in embryologic growth that allows these tumors to develop. The theory of coelomic metaplasia has gained increasing support in recent years for origin of the epithelial neoplasms of the ovary, and an invagination of the same coelomic or pertioneal epithelial layer with concurrent or subsqeunt metaplasia account for retroperitoneal mucinous neoplasmsThe preoperative course of these cysts appears indolent, yet the eoveall prognosis is poor. The role of chemotherapy in the treatment of these tumors remains undrfined. colse follow-up and aggressive management based on histologic appearance are indicated to improve the outcome of the patients with retroperitoneal mucinous cystadenocarinoam.Recently, We repoorted one case of primary retroperitoneal nucinous cytadeno -carcioma. The patient was a 32 year-old female complaing a palpable mass and discomfort in the left flank. Laparotomy revealed a huge retroperitoneal mass in the presence of bilateral normal ovaries. Histologically, it was a mucinous cystic neoplasm with flankly malignat area. No ovarian issue was found din the mass.
Adenocarcinoma, Mucinous ; Adult ; Cystadenocarcinoma, Mucinous* ; Drug Therapy ; Female ; Follow-Up Studies ; Humans ; Laparotomy ; Metaplasia ; Mucins* ; Neoplasms, Glandular and Epithelial ; Ovary ; Prognosis

Endometrial mucinous adenocarcinoma occurs in 1-9% of endometrial adenocarcinomas and adenocarcinoma with squamous differentiation in approximately 25%. We report a rare case of mucinous adenocarcinoma with squamous differentiation in a 53-year-old woman. Curetting biopsies of the endometrial lesion were taken twice after hormone replacement therapy, which lasted for four months. Because the squamous differentiation was so extensive, the initial diagnosis based on each curetting specimen was squamous papilloma. A total hysterectomy was performed and the tumor was revealed to be a mucinous adenocarcinoma with squamous differentiation. We subsequently discussed the pathogenesis and prognosis of this type of tumor.
Adenocarcinoma ; Adenocarcinoma, Mucinous* ; Biopsy ; Diagnosis ; Endometrial Neoplasms ; Female ; Hormone Replacement Therapy ; Humans ; Hysterectomy ; Middle Aged ; Mucins* ; Papilloma ; Prognosis

PURPOSE: Outcomes in patients with ovarian high-grade serous carcinoma (HGSC) treated with neoadjuvant chemotherapy (NAC) have been widely studied; however, there is limited information on responses to chemotherapy among patients with non-HGSC. The aim of this study was to compare the survival outcomes of patients with advanced-stage non-HGSC and HGSC treated with NAC. MATERIALS AND METHODS: This study was a retrospective analysis of patients with advanced-stage ovarian cancer treated at Yonsei Cancer Hospital between 2006 and 2017. The demographics, chemotherapy response, and survival rates were compared between patients with non-HGSC and those with HGSC. RESULTS: Among 220 patients who underwent NAC, 25 (11.4%) patients had non-HGSC histologic subtypes, and all received a taxane-platinum combination regimen for NAC. Patients with non-HGSC had lower baseline cancer antigen-125 levels (p < 0.001), poorer response rates (p < 0.001), lower rates of optimal cytoreduction (p=0.003), and poorer progression-free survival (PFS) (median PFS 10.3 months vs. 18.3 months; p=0.009) and overall survival (OS) (median OS 25.5 months vs. 60.6 months; p < 0.001), compared to those with HGSC. In multivariate analysis, non-HGSC was a negative prognostic factor for both PFS [hazard ratio (HR), 3.19; 95% confidence interval (CI), 1.73–5.88] and OS (HR, 4.22; 95% CI, 2.07–8.58). CONCLUSION: In this study, poorer survival outcomes were observed in patients who underwent NAC for treatment of non-HGSC versus those treated for HGSC. Different treatment strategies are urgently required to improve survival outcomes for patients with non-HGSC undergoing NAC.
Adenocarcinoma, Clear Cell ; Adenocarcinoma, Mucinous ; Cancer Care Facilities ; Demography ; Disease-Free Survival ; Drug Therapy* ; Humans ; Multivariate Analysis ; Neoadjuvant Therapy ; Ovarian Neoplasms* ; Retrospective Studies ; Survival Rate

Mucinous adenocarcinoma arising from a chronic anorectal fistula is a rare condition. It is often confused with a hemorrhoid or perineal abscess, which consequently delays accurate diagnosis. Here, we report the case of a 58-year-old man with blood-tinged stool who reported a rectal mass, which was diagnosed as mucinous adenocarcinoma arising from an anal fistula. After initial computed tomography-guided needle aspiration biopsy had failed to provide an accurate diagnosis, transrectal punch biopsy was performed to obtained adequate tissue sample for confirmative histological diagnosis. The patient was successfully treated with neoadjuvant concurrent chemoradiotherapy followed by surgical intervention.
Abscess ; Adenocarcinoma, Mucinous* ; Biopsy* ; Biopsy, Needle ; Chemoradiotherapy* ; Fistula* ; Hemorrhoids ; Humans ; Middle Aged ; Mucins* ; Needles ; Neoadjuvant Therapy ; Rectal Fistula

Thirty-five patients with locally advanced gastric carcinoma were treated with combined modalities of external radiation therapy (RT) and 5-FU based chemotherapy at the Division of Radiation Therapy, Department of Radiology, Kangnam St, Mary's Hospital, Catholic University Medical College from May 1983 to May 1987. The purpose of this retrospective study is for the evaluation of the palliative response to RT. There were 25 men and 10 women. The age ranged from 38 to 80 years (median: 56 years). The pathologic classification showed 14 (40%) poorly differentiated, 12(34%) moderately differentiated, 3 (9%) well differentiated adenocarcinomas, 2 mucinous cystadenocarcinomas, 1 signet ring cell and 3 not specified ones. The time intervals from the initial surgicopathologic diagnosis to the starting day of RT was within 1 year for 18 (51%), 1 to 2 years for 8 (23%) and 2 to 3 years for 5 (14%), respectively. The major symptoms to be treated were pain in 30 (86%), mass for 29 (83%), obstruction for 11 (31%) and jaundice for 9 (26%) patients. The response rate (patient number of positive response/total patient number) according to treated radiation doses were observed as follows; 14/16(88%) for 40~50 gy, 8/10 (80%) for over 50 gy, 6/8 (75%) for 30~40 gy and 8/15 (53%) for 20~30 gy in decreasing order. The over all survival was 3.6 months and that of 5FU+RT, FAM+RT and RT alone groups were 4.6 months, 3.7 months and 2.5 months respectively. Complications induced by RT were nausea and vomiting in 16 (46%), diarrhea in 7 (20%), leukopenia in 6 (17%) and anemia and intercurrent pneumonia in each 3 (9%) patients in decreasing order.
Adenocarcinoma ; Anemia ; Classification ; Cystadenocarcinoma, Mucinous ; Diagnosis ; Diarrhea ; Drug Therapy ; Female ; Fluorouracil ; Humans ; Jaundice ; Leukopenia ; Male ; Nausea ; Pneumonia ; Retrospective Studies ; Vomiting

OBJECTIVETo investigate the clinical manifestations, pathological characteristics, and treatments of urothelial-type mucinous adenocarcinoma of the prostate (UMAP).

METHODSWe reported a case of UMAP, reviewed relevant literature, and analyzed the clinicopaothological features, diagnosis, treatment, and prognosis of the disease.

RESULTSThe patient was a 60-year-old male and underwent transurethral resection of the prostate for dysuria. Postoperative pathology indicated mucinous adenocarcinoma and sigmoidoscopy revealed no primary colon cancer. Immunohistochemical staining showed the negative expressions of PSA and P504s and positive expressions of CK7, CK34 β E12, CK20, and CDX2. Thus UMAP was confirmed and treated by intensity-modulated radiotherapy. Then the patient was followed up for 30 months, which showed desirable therapeutic result, with neither local progression nor distant metastasis.

CONCLUSIONUMAP has a bad prognosis and its diagnosis depends on pathological and immunohistocchemical examinations. It responds well to radical prostatectomy but is not sensitive to endocrine therapy. Radiotherapy can be considered for those who are not fit to receive radical prostatectomy.

Adenocarcinoma, Mucinous ; metabolism ; pathology ; therapy ; Humans ; Keratins ; metabolism ; Male ; Middle Aged ; Neoplasm Proteins ; metabolism ; Prognosis ; Prostatectomy ; Prostatic Neoplasms ; metabolism ; pathology ; therapy ; Racemases and Epimerases ; metabolism

A case of mucinous cystadenocarcinoma arising from a mature cystic teratoma in the right ovary of a 37-year-old woman is reported. Malignant transformation of a mature teratoma is a rare event and the commonest malignant neoplasm to develop is squamous cell carcinoma.(83%) Adenocarcinoma occurs with less frequency.(6.8%) The patient was treated by staging operation followed by adjuvant chemotherapy. After six courses of combination chemotherapy, oncological investigations, including chest X-ray, abdominopelvic CT scan and tumor markers, all revealed no evidence of recurrence.
Adenocarcinoma ; Adult ; Chemotherapy, Adjuvant ; Cystadenocarcinoma, Mucinous* ; Drug Therapy, Combination ; Female ; Humans ; Mucins* ; Ovary* ; Recurrence ; Teratoma* ; Thorax ; Tomography, X-Ray Computed ; Biomarkers, Tumor

Mucinous breast carcinoma (MBC) is a rare type of breast cancer. Although patients with MBC may have a better prognosis than that of patients with invasive ductal carcinoma, many clinicians administer adjuvant chemotherapy regimens similar to those for other breast tumors. Using data from a nationwide clinical database, this study evaluated the significance of adjuvant systemic chemotherapy and whether it can be omitted in MBC patients.METHODS: We included 3,076 patients with a diagnosis of MBC recorded in the Korean Breast Cancer Registry between January 1990 and August 2016. We used the Kaplan-Meier method to analyze breast cancer-specific survival (BCCS) and overall survival (OS). Multivariate analysis was performed using a Cox proportional hazard ratio (HR) model to estimate the adjusted HR for each prognostic factor.RESULTS: A total of 2,988 MBC patients were enrolled and followed-up for a median of 100 months (range, 2–324 months). Multivariate analysis revealed that axillary lymph node (ALN) metastasis and estrogen receptor (ER) negativity were significant prognostic factors for BCSS. Meanwhile, old age, pathologic tumor stage, and ALN metastasis were significant prognostic factors for OS. Subgroup analysis of ER-positive MBC showed that ALN metastasis was a significant prognostic factor for BCSS. Additionally, old age, pathologic tumor stage, and ALN metastasis were prognostic factors for OS. Ultimately, ALN metastasis was the most statistically significant prognostic factor for MBC. However, chemotherapy had no significant effect on BCSS and OS. The Kaplan-Meier curves of BCSS and OS based on pathologic tumor and nodal stages and age revealed that chemotherapy did not statistically significantly improve prognosis, except for the N3 stage.CONCLUSION: Our large retrospective analysis revealed that adjuvant chemotherapy provided little benefit to improve the prognosis of most ER-positive MBC patients. Therefore, chemotherapy can be omitted in the treatment of most ER-positive MBC.]]>
Adenocarcinoma, Mucinous ; Breast Neoplasms ; Breast ; Carcinoma, Ductal ; Chemotherapy, Adjuvant ; Diagnosis ; Drug Therapy ; Estrogens ; Humans ; Lymph Nodes ; Methods ; Mucins ; Multivariate Analysis ; Neoplasm Metastasis ; Prognosis ; Retrospective Studies

Intraductal papillary mucinous neoplasm (IPMN) is frequently found recently and is a precancerous lesion. Main duct-type should be resected since it can easily progress to invasive IPMN, whereas branch duct-type (BD) usually remains silent without malignant transformation. BD-IPMN should be resected if it has mural nodule, thick wall or septum, or solid component which are the obvious risk factors for malignancy. If the cyst size of BD-IPMN is more than 3 cm in diameter without obvious risk factors, it can be followed-up regularly or can be treated either with surgical resection or endoscopic ultrasonography (EUS)-guided ethanol lavage. Small BD-IPMN less than 3 cm in size without risk factors can be followed up with sonography, CT scan or EUS annually.
Adenocarcinoma, Mucinous/diagnosis/pathology/*therapy ; Carcinoma, Pancreatic Ductal/diagnosis/pathology/*therapy ; Carcinoma, Papillary/diagnosis/pathology/*therapy ; Diagnosis, Differential ; Ethanol/therapeutic use ; Humans ; Pancreatic Neoplasms/diagnosis/pathology/*therapy ; Risk Factors ; Tomography, X-Ray Computed

The patient was a 70-year-old male whose chief complaints were obstructive jaundice and weight loss. Abdominal imaging studies showed a 2.5 cm sized mass at the distal common bile duct, which was suggestive of bile duct cancer. Eccentric enhancing wall thickening in the transverse colon was also shown, suggesting concomitant colon cancer. A colonoscopy revealed a lumen-encircling ulcerofungating mass in the transverse colon, that was pathologically proven to be adenocarcinoma. The bile duct pathology was also adenocarcinoma. Pylorus-preserving pancreaticoduodenectomy and extended right hemicolectomy were performed under the diagnosis of double primary cancers. Postoperative histopathologic examination revealed moderately differentiated mucinous adenocarcinoma of transverse colon cancer, and mucinous adenocarcinoma of the distal common bile duct. Immunohistochemical staining studies showed that the bile duct cancer had metastasized from the colon cancer. The patient recovered uneventfully from surgery and will be undergoing chemotherapy for three months.
Adenocarcinoma ; Adenocarcinoma, Mucinous* ; Aged ; Bile Duct Neoplasms ; Bile Ducts ; Colon, Transverse* ; Colonic Neoplasms ; Colonoscopy ; Common Bile Duct Neoplasms ; Common Bile Duct* ; Diagnosis ; Drug Therapy ; Humans ; Jaundice, Obstructive* ; Male ; Mucins* ; Neoplasm Metastasis ; Pancreaticoduodenectomy ; Pathology ; Weight Loss